The Vanguard FTSE All-World ex-US ETF (VEU) currently trades at a compelling valuation of about 12.5 times price-to-earnings with an 8% earnings yield, outperforming the SPY year-to-date despite a stronger dollar. Its broad diversification, solid momentum, and record dividend payout support a buy rating, with technical analysis indicating favorable risk/reward near $83 support. The ETF benefits from AI-driven growth in South Korea and Taiwan and rising earnings forecasts, although weakness in European and Japanese markets remains a concern. Seasonal trends suggest possible short-term consolidation but historically bullish November performance and a healthy long-term uptrend confirmed by the 200-day moving average reinforce the positive outlook.
The Vanguard FTSE All-World ex-US ETF (VEU) is the subject, with Pluang market data as context. As of Sep 19, 2026 03:03 WIB, out of 150 priced US stocks tradable on Pluang, 66 rose and 83 fell. Notable movers include IQ (IQIYI Inc - ADR) at USD 1.13 with a 1-day change of +4.63% and Pluang order activity of 83% Buy, Alibaba Group (BABA) at USD 113.36 with a +4.45% change and 55% Sell order activity, and Netflix Inc (NFLX) at USD 72.04 with a -4.34% change and 63% Buy order activity. The most notable figure is IQ's 83% Buy order activity.
A webinar titled "Ready for AI?" scheduled for October 29, 2026, will discuss how artificial intelligence is reshaping public relations by changing how information is found, evaluated, and shared. Experts will share insights on maintaining message vi...
17a-4 LLC introduced DataParser Hub, an API that enables clients to integrate proprietary messaging and collaboration data into Microsoft 365 Purview and Copilot. This solution supports over 30 data types from platforms like Slack, Zoom, and Webex, a...
IBA has treated the first patient in the C-FLASH-01 clinical trial, the first human study testing ConformalFLASH® proton therapy. This trial, conducted at Penn Medicine with FDA approval, explores the feasibility of using ultra-high dose rate proton ...
IBA has treated the first patient in the C-FLASH-01 clinical trial, testing its ConformalFLASH® proton therapy for head and neck cancer re-irradiation. This trial, led by Penn Medicine and approved by the FDA, explores ultra-high dose rate proton the...
WISeQey Corp. completed its redomiciliation and began trading on Nasdaq and the SIX Swiss Exchange, marking a new phase focused on integrating its quantum cybersecurity, digital identity, and space IoT technologies. Its subsidiary WISeSat.Space also ...
